250 Industry Drive
Pittsburgh, PA 15275

Revvity Omics, Inc.

Phone: 1-866-463-6436
Fax: 1-412-220-0784

PATIENT DATA	FILTER PAPER DATA	SUBMITTER DATA
Name: RIVAS MACIAS, WENDY JUDI	**Filter Paper:** MET2602896	Submitter: ANA PAOLA MACIAS ROBLES CMN DE OCCIDENTE IMSS
AKA Name:	Accession No: 2602896	
Birth Date: 2010-Sep-01 00:00	Date Collected: 2026-Apr-21 00:00	MEXICO
Sex: F	Date Recvd: 2026-May-08	
Med. Rec.	Completed: 2026-May-18	
PS ID: 11835718	Print Date: 2026-May-18	Physician: ANA PAOLA MACIAS ROBLES
		Phone:
		Initial Release: 2026-May-18 14:58

Symptoms:

LABORATORY REPORT FOR Revvity Omics PROGRAM

HAEINH
Antigenic C1-INH

Result: Within Normal Limits
HAEINH = 146.13 µg/mL (Normal range > 126.66 µg/mL)

HAEC4
Antigenic C4

Result: Within Normal Limits
HAEC4 = 172.31 µg/mL (Normal range > 89.57 µg/mL)

HAEENZ
Hereditary Angioedema Functional C1 Inhibitor Assay

Result: Within Normal Limits
fC1-INH = 89.9 % della media normale (intervallo normale: > 62,8%)

I risultati non sono suggestivi di angioedema ereditario (tipo I o tipo II). I risultati forniti sono da intendersi come un supporto nella diagnosi di angioedema ereditario. Per confermare o escludere una diagnosi, considerare i risultati in combinazione con la presentazione clinica del paziente e fare riferimento alle attuali linee guida per la gestione dell'HAE, che raccomandano che tutti i pazienti con sospetto di HAE vengano sottoposti ai test di laboratorio per la determinazione dei livelli ematici di C1-Inh funzionale, C1-Inh quantitativo e C4.
In questo caso, considerare altri tipi di angioedema.

fC1-INH = 89.9 % of normal mean (Normal Range: > 62.8 %)
Results are not indicative of Hereditary Angioedema (Type I or Type II). The results provided are intended to serve as an aid in the diagnosis of hereditary angioedema. To confirm or rule out a diagnosis, please consider the results in combination with the clinical spectrum of the patient and refer to current guidelines for the management of HAE, which recommend that all patients suspected to have HAE are assessed for blood levels of C1-INH function, C1-INH protein, and C4. Consider other types of Angioedema.
fC1-INH = 89.9 % sredniej normy (zakres normy: > 62,8%) Wyniki nie wskazuja na dziedziczny obrzek naczynioruchowy (typ I lub typ II). Przedstawione wyniki maja sluzyc jako pomoc w diagnostyce dziedzicznego obrzeku naczynioruchowego. Aby potwierdzic lub wykluczyc diagnoze, nalezy rozwazyc wyniki w polaczeniu ze spektrum klinicznym pacjenta i zapoznac sie z aktualnymi wytycznymi dotyczacymi postepowania w HAE, które

Taraka Donti, PhD, FACMG Laboratory Director

250 Industry Drive
Pittsburgh, PA 15275

Revvity Omics, Inc.

Phone: 1-866-463-6436
Fax: 1-412-220-0784

PATIENT DATA	FILTER PAPER DATA	SUBMITTER DATA
Name: RIVAS MACIAS, WENDY JUDI	**Filter Paper:** MET2602896	Submitter: ANA PAOLA MACIAS ROBLES CMN DE OCCIDENTE IMSS
AKA Name:	Accession No: 2602896	
Birth Date: 2010-Sep-01 00:00	Date Collected: 2026-Apr-21 00:00	MEXICO
Sex: F	Date Recvd: 2026-May-08	
Med. Rec.	Completed: 2026-May-18	
PS ID: 11835718	Print Date: 2026-May-18	Physician: ANA PAOLA MACIAS ROBLES
		Phone:
		Initial Release: 2026-May-18 14:58

Symptoms:

zalecaja, aby wszyscy pacjenci z podejrzeniem HAE zostali ocenieni pod katem poziomu funkcji C1-INH, bialka C1-INH i C4 we krwi. Nalezy rozwazyc inne rodzaje obrzeku naczynioruchowego.

Comments:

Methodology: The analyte concentrations were measured via tandem mass spectrometry.

Il controllo qualità per questo esame è stato considerato accettabile prima dell'emissione di questi risultati. Le concentrazioni degli analiti sono state misurate tramite spettrometria di massa tandem.

Kontrola jakosci tego oznaczenia przed udostepnieniem wyników byla zadowalajaca. Stezenie analizowanych substancji mierzono za pomoca tandemowej spektrometrii mas.

This test was developed, and its performance characteristics determined by Revvity Omics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity testing.

Questo test è stato sviluppato da Revvity Omics, Inc., che ne ha anche determinato le caratteristiche di performance. Non è stato autorizzato né approvato dalla Food and Drug Administration (FDA) degli Stati Uniti. La FDA ha stabilito che tale autorizzazione/approvazione non è necessaria. Questo test è utilizzato per scopi clinici. Non deve essere considerato sperimentale o a scopo di ricerca. Questo laboratorio è certificato come qualificato a eseguire test di alta complessità secondo le norme contenute nel Clinical Laboratory Improvement Amendments del 1988 (CLIA-88).

To badanie zostalo opracowane przez firme Revvity Omics, Inc., która równiez okreslila charakterystyke jego parametrów. Badanie nie jest zatwierdzone przez amerykanska Agencje Zywnosci i Leków (ang. Food and Drug Administration, FDA) ani nie posiada jej pozwolenia na dopuszczenie do obrotu. Agencja FDA uznala, ze takie pozwolenie nie jest wymagane. Badanie nalezy stosowac do celów klinicznych. Badania nie nalezy traktowac jako eksperymentalne lub stosowac do celów naukowych. Niniejsze laboratorium posiada uprawnienia do wykonywania badan o wysokim.

Reference ranges for hereditary angioedema related tests were established using adult samples. Clinical correlation is required for interpretation of results from individuals of 1 to 18 years of age. Functional C1-INH, antigenic C1-INH, and antigenic C4 assays are not appropriate for individuals < 12 months of age.

Sara Smith, PhD, Manager, Metabolic Laboratory, Revvity Omics
Taraka Donti, PhD, FACMG, Director of Metabolic Laboratory, Revvity Omics

Taraka Donti, PhD, FACMG Laboratory Director